Mike Strazzella, Practice Group Leader of Buchanan's Federal Government Relations practice and head of the firm's Washington D.C. office, comments on the White House's moves to lower drug costs by exploring the consolidation of coverage for prescription medicines under Medicare's drug program instead of its doctors program. Mike warns of its difficulty in The Washington Post's "The Health 202: There's a Fight Brewing Between the Trump Administration and Drugmakers."